Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former FDAer joins GPhA regulatory affairs

Executive Summary

Former FDA Office of Generic Drugs Deputy Director Gordon Johnston is joining the Generic Pharmaceutical Association as VP-regulatory affairs. Johnston worked at FDA for 12 years, leaving OGD in January 1999 to join fellow former OGD Deputy Director Robert Pollack at Lachman Consultant Services (1"The Pink Sheet" Nov. 9, 1998, In Brief)...

You may also be interested in...

FDA Office of Generic Drugs

Deputy Director Gordon Johnston will depart from OGD Jan. 1 following acceptance of an associate position at Lachman Consultant Services. Johnston will be joining former OGD Deputy Director and Lachman VP Robert Pollock. OGD Labeling and Program Support Division Director Jerry Phillips begins a new post at the end of November as associate director for medication errors in the newly established Office of Post-marketing Drug Risk Assessment ("The Pink Sheet" Nov. 2, p. 6). Phillip's vacated position will be filled by Consumer Safety Officer Robert West. Division of Chemistry II Director Frank Holcombe will become OGD acting associate director for chemistry, and will be replaced by Florence Fong

Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%

Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.

Subtracting Rx Adds To Perrigo OTC Pipeline

In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts